Health-Related Quality of Life in Pediatric Hepatic Glycogen Storage Disease: A Dual-Perspective Study

Oznur Aydin1, Selcuk Dagdelen2, Hasan Ozen3

  • 1Department of Nutrition and Dietetics, Faculty of Health Sciences, Hacettepe University, Ankara 06100, Türkiye.

Nutrients
|July 15, 2026
PubMed

Insights

Children with hepatic glycogen storage diseases (GSDs) have reduced health-related quality of life (HRQoL) compared to healthy peers. Assessments from both children and parents reveal significant impacts on daily functioning and well-being.

Area of Science:

  • Metabolic disorders
  • Pediatric health
  • Quality of life research

Background:

  • Hepatic glycogen storage diseases (GSDs) are rare inherited metabolic disorders.
  • Lifelong nutritional management and metabolic control are essential for GSDs.
  • These management strategies may negatively impact health-related quality of life (HRQoL).

Purpose of the Study:

  • To evaluate HRQoL in children with hepatic GSD using child and parent reports.
  • To compare HRQoL findings with normative data.
  • To explore associations between HRQoL and biochemical, anthropometric, and nutritional parameters.

Main Methods:

  • Included 23 children with hepatic GSD and their parents.
  • Assessed HRQoL using the Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale.
  • Compared child and parent reports with normative data and analyzed associations using correlation analyses.

Main Results:

  • Children with hepatic GSD reported significantly lower HRQoL scores than healthy children and those with other chronic diseases.
  • Parents reported lower HRQoL scores than children, especially in psychosocial, social, and school functioning.
  • Body composition and nutritional treatment burden correlated with certain HRQoL domains.

Conclusions:

  • Children with hepatic GSD experience impaired HRQoL from both child and parent perspectives.
  • Integrating HRQoL assessment into routine care can identify unmet needs.
  • Individualized nutritional management may be improved by considering HRQoL.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...